NL-OMON54286
Recruiting
Phase 4
Prediction of Response Of horMOnal Treatment in advanced and recurrent Endometrial cancer - PROMOTE study
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Radboud Universitair Medisch Centrum
- Enrollment
- 130
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer
- •All histologic types of endometrial carcinoma
- •Planned treatment with any type of hormonal therapy
- •Biopsy taken within 120 days prior to start of hormonal therapy with no
- •intercurrent therapy between biopsy and start of hormonal therapy
- •In metastatic EC, histological sampling of one distant metastasis is
- •recommended
Exclusion Criteria
- •Adjuvant hormonal therapy immediately started after surgery
- •Synchronous use of hormonal therapy for other indications
- •Endometrial sarcoma or endometrial stroma cell sarcoma
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Comparison between different doses of gonadotropin-releasing hormone agonist used in short stimulation protocol in infertile women undergoing IVFInfertilityReproductive Health and Childbirth - Fertility including in vitro fertilisationACTRN12613000384752Sarhan IVF Cntre90
Active, not recruiting
Not Applicable
MIrena coil to Reduce Endometrial Neoplastic AbnormalitiesEndometrial hyperplasia and endometrioid adenocarcinoma of the endometriumCancerISRCTN31662931Central Manchester University Hospitals NHS Trust (CMFT) (UK)150
Not yet recruiting
Phase 4
Early mental response to hormonal treatment in transgender men - The EMRE Study2024-517052-35-00Karolinska University Hospital70
Completed
Phase 2
Effect of hormonal therapy versus no treatment on testicular histopathology and fertility in patients with non-obstructive azoospermianon-obstructive azoospermia.Male infertilityIRCT201612069014N137Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences28
Active, not recruiting
Not Applicable
Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line hormonal therapyFemale patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapyMedDRA version: 14.1Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-000155-16-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI